- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- TTI-101, Placebo
- Drug
- Lead sponsor
- Tvardi Therapeutics, Incorporated
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • La Jolla, California • Orange, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 596
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Atorvastatin, Placebo Oral Tablet
- Drug · Other
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BMS-986020, Placebo matching with BMS-986020
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder, Anxiety Disorders, Anxiety Depression
- Interventions
- Palliative Care, Standard of Care
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone, Untreated Cohort
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Plymouth, Pennsylvania
- Conditions
- Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
- Conditions
- Interstitial Lung Disease
- Interventions
- alternative six minute walk test, Standard six minute walk test
- Procedure
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
- Interventions
- Semaglutide Pen Injector
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Blood draw, Questionnaire
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Scleroderma
- Interventions
- MRI, Hyperpolarized Xe129, HRCT
- Diagnostic Test · Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Idiopathic Pulmonary Fibrosis, IPF
- Interventions
- Tazarotene (GRI-0621), Placebo
- Drug
- Lead sponsor
- GRI Bio Operations, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- 20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray
- Drug · Other
- Lead sponsor
- Cellular Sciences, inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Hialeah Gardens, Florida
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
- Interventions
- Fingolimod, Placebo
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- N-acetyl cysteine, Placebo
- Drug
- Lead sponsor
- Fernando J Martinez
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Los Angeles, California • Stanford, California + 22 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Ambrisentan, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- N-acetyl-cysteine, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis, Cough
- Interventions
- Thalidomide, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
- Interventions
- Nerandomilast, Placebo matching nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Valganciclovir, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 5
- States / cities
- Hershey, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG), Microscopic Polyangiitis (MPA), ANCA-Associated Vasculitis (AAV), Vasculitis
- Interventions
- Online questionnaire
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Philadelphia, Pennsylvania
- Conditions
- Bronchiectasis
- Interventions
- hMSCs
- Biological
- Lead sponsor
- Marilyn Glassberg
- Other
- Eligibility
- 30 Years to 87 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Progressive Pulmonary Fibrosis, Interstitial Lung Disease
- Interventions
- SUPPORT-T Educational Intervention
- Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina